{
  "ticker": "LDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959567",
  "id": "02959567",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0945",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvr7rlb1dmp0.pdf",
  "summary": "- **Milestone Achievement**: Enrolled 500th patient in FebriDx CLIA waiver study, triggering **US$298,457** payment from BARDA.  \n- **Progress**: 78/120 bacterial-positive patients enrolled (65% of target); current bacterial prevalence rate ~35% post-enrichment strategy.  \n- **Next Milestone**: **US$746,143** payment upon Last Patient Enrolled.  \n- **Timeline**: Study completion expected **Q4 CY2025**; FDA CLIA waiver submission targeted for **October 2025**.  \n- **Market Potential**: CLIA waiver could unlock **US$1.0 billion+** U.S. addressable market.  \n\n*Omitted: Operational details, forward-looking statements, and non-material commentary.*",
  "usage": {
    "prompt_tokens": 1450,
    "completion_tokens": 163,
    "total_tokens": 1613,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T00:01:29.886690"
}